Reproducibility of whole-body 131I scan and serum thyrotropin and stimulated thyroglobulin values in patients studied twice after injection of recombinant human thyrotropin

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 3, 2007, Pages 363-367

  Niederkohr, Ryan D ^a   McDougall, I Ross ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Radioiodine treatment; Thyroid; Thyroid cancer

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROTROPIN; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; FEMALE; HUMAN; IODINE 131 UPTAKE TEST; MALE; REPRODUCIBILITY; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STUDENT T TEST; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; WHOLE BODY SCINTISCANNING; BLOOD; DRUG ADMINISTRATION; GENETICS; METHODOLOGY; MIDDLE AGED; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; WHOLE BODY IMAGING;

ADOLESCENT; ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROTROPIN; WHOLE BODY IMAGING;

EID: 33847124001     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0227-y     Document Type: Article

References (19)

1. Mazzaferri E, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
2. Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract 2000;6:469-76.
3. Schlumberger M. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306.
4. Cohen JB, Kalinyak JE, McDougall IR. Modern management of differentiated thyroid cancer. Cancer Biother Radiopharm 2003;18:689-705.
5. Mandel SJ, Shankar LK, Benard F, Yamamoto A, Alavi A. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 2001;26:6-9.
6. 131I scans. Nucl Med Commun 2004;25:129-34.
7. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337:888-96.
8. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-85.
9. Durski JM, Weigel RJ, McDougall IR. Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer. Nucl Med Commun 2000;21:521-8.
10. Ladenson PW. Recombinant thyrotropin for detection of recurrent thyroid cancer. Trans Am Clin Climatol Assoc 2002;113:21-30.
11. McDougall I, Weigel RJ. Recombinant human thyrotropin in the management of thyroid cancer. Curr Opin Oncol 2001;13:39-43.
12. Becker D, Charkes ND, Hurley JR, McDougall IR, Price DC, Royal HD, et al. Society of Nuclear Medicine Procedure Guideline for thyroid scintigraphy, version 2.0. Accessible online at http://interactive.snm.org/docs/pg_ch05_0403. pdf. Accessed 6/7/2006.
13. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Thyroid 2006;16:109-42.
14. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002;26:879-85.
15. Dow K, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997;7:613-9.
16. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006;91:878-84.
17. Park H, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994;4:49-54.
18. 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 1997;18:505-12.
19. Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassman M, Hanscheid H, et al. Comparison of radiobiokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 2003;30:1371-7.